Is there a vaccine for the Coronavirus?

Not yet, but there are plenty of scientists and organizations working on developing a vaccine. The first Coronavirus vaccine trial started March 16, 2020 in Seattle.

A preprint study (not yet peer reviewed) of the vaccine being developed by Oxford University and AstraZeneca released May 13th showed that vaccinated macaques were protected from COVID pneumonia.    

Moderna (Cambridge,MA) last week announced completion of phase 1 of its human coronavirus vaccine trial.  It had only 8 subjects but demonstrated acceptable safety data to move on to phase 2 trials.  They added that all 8 subjects developed neutralizing antibodies which should protect against severe COVID disease.

China’s vaccine candidate, which uses an adenovirus vector to deliver the vaccine’s genetic material, has also completed phase 1, with safety data published in The Lancet May 22nd.  Subjects all had rapid binding antibody and neutralizing antibody responses following vaccination.  However, they observed that subjects with preexisting antibodies to the adenovirus used in the vaccine had lower immune responses.

Novavax this week announced it had begun clinical trials in Australia.  Novavax was an early frontrunner among smaller biotechs, receiving $388M from Gates-backed CEPI.  It too has an aggressive timeline, but is also leveraging global manufacturing partners in China and India, scientific partnerships with the Serum Institute and Oxford University to be able to produce any one of dozens of vaccine candidates in the works worldwide, including in their new plant in the Czech Republic which they say will be capable of 100 million vaccine doses per month by January 2021.